Case Report

Dilemma on Indonesian adult with micropenis during COVID-19 pandemic: A case report and review article

Karin Dhia Fahmita, Deasy Ardiany*

Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

ARTICLE INFO

Keywords:
Access and reproductive healthcare
Gonadotropin
Micropenis
Testosterone

ABSTRACT

Background: Micropenis usually has a series of causative factors that must be identified to determine the treatment modality.

Case presentation: A 24-years-old Indonesian male complained of a small penis since infancy. The patient has a short penis size (3 cm), no pubic hair, small scrotum, both testes cannot hide palpable, and tanner scale 2. The hormonal examination includes testosterone hormone of 14.94 ng/dL, luteinizing hormone of 14.89 mUI/mL, and follicle-stimulating hormone of 67.51 mUI/mL. Ultrasound showed no testicular location and only a prostate-like appearance of a size of 0.6 × 2.07 cm on the abdomen. The patient will receive therapy but was constrained by the COVID-19 pandemic.

Discussion: diagnosis of micropenis and gonadotropin hormone disorders must be detected early and receive treatment immediately for better results.

Conclusion: Micropenis is a medical diagnosis that depends on proper examination and management, and early diagnosis is essential to improve prognosis.

1. Introduction

Micropenis is used in clinical practice to refer to a penis that is shorter than expected [1]. The incidence of micropenis is 1.5 of 10,000 male newborns [2,3], while Indonesia still has no data reporting on this incidence [4]. Micropenis usually has a series of causative factors that must be identified to determine the treatment modality. This condition is usually the result of a defect in the hypothalamic-pituitary-gonadal (HPG) axis. It can be looked for based on three causes, hypergonadotropic hypogonadism due to primary testicular disorders, hypogonadotropic hypogonadism secondary to hypothalamic-pituitary dysfunction, and idiopathic if all three are absent [5,6]. Based on the description above, we are interested in reporting cases of micropenis in Indonesian males. We report based on SCARE 2020 Guidelines [7].

1.1. Case presentation

A 24-years-old Indonesian male complained of a small penis since infancy. The patient feels that his body is shorter than his peers, and the patient feels that his height has not increased since junior high school. The patient was the youngest of 2 siblings, and the patient’s older brother does not have penis and growth problems like other family members. History of comorbidities and other congenital disabilities was denied. Physical investigation showed a body height of 153 cm, penis length of 3 cm, no pubic hair, small scrotum, both testes could not become palpable, and tanner scale 2 (Fig. 1) [8,9]. The hormonal examination included testosterone hormone of 14.94 ng/dL, luteinizing hormone of 14.89 mUI/mL, and stimulating follicle hormone of 67.51 mUI/mL. Ultrasound showed no testicular location and only a prostate-like appearance of a size of 0.6 × 2.07 cm above the bilateral adnexal area (Fig. 2). Chromosomal examination results obtained 46, XY.

The patient was tested for human chorionic gonadotropin stimulation in which the patient received gonadotropin hormone as much as 2000 IU × 3 days. On the fourth day, the result was 0.106 ng/dL. Subsequently, the patient underwent laparoscopy, which revealed that the testes were atrophy in the bilateral intracanalicular but had not been opened and explored further. The patient was then diagnosed with bilateral undescended testes and micropenis. The patient was planned

* Corresponding author. Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Jl. Mayjend Prof. Dr. Moestopo No. 6-8, Airlangga, Gubeng, Surabaya, East Java, 60286, Indonesia.
E-mail address: deasy.ardiany22@gmail.com (D. Ardiany).

https://doi.org/10.1016/j.amsu.2022.104244
Received 11 June 2022; Received in revised form 17 July 2022; Accepted 20 July 2022
Available online 31 July 2022
2049-0801/© 2022 The Author(s). Published by Elsevier Ltd on behalf of LJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
for testicular exploration bilateral orchidectomy. Subsequent testosterone hormone replacement therapy, but the patient had not returned to control due to the COVID-19 pandemic.

2. Discussion

Micropenis is commonly associated with testosterone deficiency from 12 weeks of gestation, in which testosterone is induced by gonadotropin hormone during organogenesis [2]. At the same time, the testes differentiate in the first trimester of pregnancy [10]. Males who are severely deficient and who have not been adequately treated previously will show the clinical features of marked prepubertal hypogonadism, such as testes, small penis, cryptorchidism, gynecomastia, high-pitched voice, non-closing epiphysis, linear growth to adulthood, Eunuchoid habitus, body hair/sparse facial features, infertility, low bone mass, sarcopenia, lack of sexual desire/activity. Therefore, the history should also include information about puberty, secondary sex signs and hypogonadism. A history of previous systemic disease is used to rule out the suspicion of acquired hypogonadism [11–13].

Undescended testes (cryptorchismus) are common conditions in which one or both testicles do not fully descend from the abdomen into the scrotum during pregnancy. Testicles that have been in an undescended position for several years cannot produce normal spermatozonia and are at significant risk of becoming malignant (testicular germ cell tumor). Thus, resection (orchidectomy) is recommended for late-arriving cryptorchidism in children or young adults. If refused, careful surveillance of malignancy should be carried out. Laparoscopy and orchidectomy are recommended in young adult cryptorchid patients with non-palpable testes and testosterone replacement therapy (TRT). Artificial testicular insertion after bilateral orchidectomy may also be recommended [14].

With early treatment, the prognosis of micropenis due to hormone deficiency is good. They usually respond well to testosterone therapy, gain adequate penis length (albeit below average), and function normally as adults [15]. Regarding fertility, studies on untreated bilateral UDT found that 100% will have oligospermia and 75% will have azoospermia. Among those successfully treated, 75% remained oligospermia and 42% azoospermic. Regarding the preservation of fertility potential,
early surgical correction is strongly recommended before 12 months and no later than 18 months. The relative risk of malignancy in patients undergoing UDT therapy before puberty is 2.2 and increases to 5.4 in patients undergoing postpubertal therapy compared to the general population [16].

Micropenis impacts a person’s confidence in dealing with the opposite sex and makes the sexual quality less than optimal [17]. So that it dramatically affects the quality of life because micropenis is a disease that is not life-threatening. Its handler is pending due to limited health personnel during the COVID-19 Pandemic. Because the cause of micropenis is related to hormones, the worst complication is fertility, which causes the patient’s quality of life to be low [17,18]. The limitation of this study was that it took a long time to report treatment prognosis due to the COVID-19 pandemic.

3. Conclusion

Micropenis is a medical diagnosis that depends on proper examination and management. Micropenis can occur due to pituitary/hypothalamic insufficiency, primary testicular insufficiency, or idiopathic. In this case, the micropenis is caused to primary testicular insufficiency, resulting in impaired development and growth. Endocrinological assessment helps in determining the etiology of the micropenis. Early diagnosis is essential for various treatment options and a better prognosis.

Research registration

Not applicable.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Guarantor

Deasy Ardiany is the person in charge of the publication of our manuscript.

Ethical approval

Not applicable.

Funding

None.

Author contribution

All authors contributed toward data analysis, drafting and revising the paper, gave final approval of the version to be published and agree to be accountable for all aspects of the work.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Declaration of competing interest

Karin Dhia Fahmita and Deasy Ardiany declare that they no conflict of interest.

Acknowledgement

We would like to thank our editor, “Fis Citra Ariyanto”.

*Fig. 2. Imaging abdomen ultrasound.*
References

[1] M.R. Stancampiano, K. Suzuki, S. O’Toole, G. Russo, G. Yamada, S. Faisal Ahmed, Congenital micropenis: etiology and management, J. Endocr. Soc. 6 (2) (2022) bvab172, https://doi.org/10.1210/jendso/bvab172.

[2] N. Hatipoğlu, S. Kurtoglu, Micropenis: etiology, diagnosis and treatment approaches, J. Clin. Res. Pediatric Endocrinol. 5 (4) (2022) 217–223, https://doi.org/10.4274/jcrpe.1135.

[3] J.H. Han, J.P. Lee, J.S. Lee, S.H. Song, K.S. Kim, Fate of the micropenis and constitutional small penis: do they grow to normalcy in puberty? J. Pediatr. Urol. 15 (5) (2019) 526, https://doi.org/10.1016/j.jpeduro.2019.07.009, e1–e6.

[4] M. Faizi, T. Dyah, L. St, N. Ep, Penile length of newborn infant in Dr. Soetomo Hospital Surabaya. A preliminary study, Folia Medica Indonesiana 47 (1) (2011) 64–67.

[5] R. Fraietta, D.S. Zylberstejn, S.C. Esteves, Hypogonadotropic hypogonadism revisited, Clinics 68 (1) (2013) 81–88, https://doi.org/10.6061/clinics/2013 (sup01)09.

[6] R.B. Nerli, A.K. Guntaka, P.B. Patne, M.B. Hiremath, Penile growth in response to hormone treatment in children with micropenis, Indian J. Urol : IJU : journal of the Urological Society of India 29 (4) (2013) 288–291, https://doi.org/10.4103/0970-1591.120107.

[7] R.A. Agha, T. Franchi, C. Sohrabi, G. Mathew, A. Kerwan, The SCARE 2020 guideline: updating consensus surgical Case REnter (SCARE) guidelines, Int. J. Surg. 84 (2020) 226–230, https://doi.org/10.1016/j.ijsu.2020.10.034.

[8] B.S. Miller, K. Sarafoglou, O.Y. Addo, Development of Tanner stage-age adjusted CDC height curves for research and clinical applications, J. Endocr. Soc. 4 (9) (2020) bvaa098, https://doi.org/10.1210/jendso/bvaa098.

[9] Sunarja NW, Barmadiastri, I.O. Wiyogo, Staged repair on a neglected paraphimosis in a 5-year-old-male, J. Pediatric Surg. Case Reports 72 (2021), 101985, http://doi.org/10.1016/j.epsc.2021.101985.

[10] R.A. Rey, R.P. Grinspon, Androgen treatment in adolescent males with hypogonadism, Am. J. Men’s Health 14 (3) (2020), 155798320922443, https://doi.org/10.1177/155798320922443.

[11] A.M. Sugianto, S.A. Soelistijo, A female with isolated hypogonadotropic hypogonadism: a case report and review article, Ann. Med. Surg. (2012), https://doi.org/10.1016/j.amsu.2022.103289, 2022;74:103289.

[12] C. Pakpahan, B. Amanda, B. Humidah, R. Yuviasti, Case report: a woman 27 year old with mosaic turner syndrome associate hypogonadotropic hypogonadism, Indonesian Androl. Biomed. J. 1 (2) (2020) 42–47.

[13] A. Salonia, C. Bettocheli, L. Boeri, P. Capogrosso, J. Carvalho, N.C. Gilesiz, et al., European association of urology guidelines on sexual and reproductive health-2021 update: male sexual dysfunction, Eur. Urol. 80 (3) (2021) 333–357, https://doi.org/10.1016/j.eururo.2021.06.007.

[14] J.M. Chung, S.D. Lee, Individualized treatment guidelines for postpubertal cryptorchidism, World J. Men’s Health 33 (3) (2015) 161–166, https://doi.org/10.5534/wjmh.2015.33.3.161.

[15] S. Tsang, When size matters: a clinical review of pathological micropenis, J. Pediatr. Health Care : official publication of National Association of Pediatric Nurse Associates & Practitioners 24 (4) (2010) 231–240, https://doi.org/10.1016/j.pedhc.2009.05.001.

[16] J. Shin, G.W. Jeon, Comparison of diagnostic and treatment guidelines for undescended testis, J. Urol. 185 (3) (2015) 155798320922443, https://doi.org/10.1016/j.juro.2015.03.0894.

[17] L. Dunkel, R. Quinton, Transition in endocrinology: induction of puberty, Eur. J. Endocrinol. 170 (6) (2014) R229–R239, https://doi.org/10.1530/eje-13-0894.

[18] E. Wibisono, U. Hadi, Bramantono, M.V. Arfijanto, M. Rusli, B.E. Rahman, et al., National early warning score (NEWS) 2 predicts hospital mortality from COVID-19 patients, Ann. Med. Surg. (2012), https://doi.org/10.1016/j.amsu.2022.103462, 2022;76:103462.